What is HC Wainwright’s Estimate for Cybin Q1 Earnings?

Cybin Inc. (NASDAQ:HELP) – Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Cybin in a research report issued on Thursday, July 9th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.80) per share for the quarter. The consensus estimate for Cybin’s current full-year earnings is ($3.49) per share. HC Wainwright also issued estimates for Cybin’s Q2 2027 earnings at ($0.80) EPS, Q3 2027 earnings at ($0.80) EPS, Q4 2027 earnings at ($0.61) EPS, Q1 2028 earnings at ($0.61) EPS, Q2 2028 earnings at ($0.50) EPS, Q3 2028 earnings at ($0.50) EPS, Q4 2028 earnings at ($0.50) EPS and FY2031 earnings at $3.23 EPS.

Separately, TD Cowen initiated coverage on shares of Cybin in a research report on Monday, April 13th. They set a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $55.00.

Cybin Stock Performance

Shares of HELP opened at $6.63 on Friday. Cybin has a 1 year low of $3.76 and a 1 year high of $9.12. The firm’s 50 day moving average is $5.01. The stock has a market cap of $457.47 million, a price-to-earnings ratio of -1.57 and a beta of 0.62.

Cybin (NASDAQ:HELP) last issued its earnings results on Monday, June 29th. The company reported $0.00 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Cybin

Several large investors have recently bought and sold shares of HELP. Millennium Management LLC raised its stake in Cybin by 1,388.5% during the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock valued at $8,414,000 after purchasing an additional 959,448 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Cybin by 46.7% in the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock worth $63,000 after buying an additional 2,400 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after buying an additional 11,790 shares in the last quarter. Institutional investors own 17.94% of the company’s stock.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.